Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients
Yun Kyoung Tiger(Center for Cancer and Blood Disorders), Marc Hoffmann(The University of Kansas Cancer Center), Christopher R. D’Angelo(Susan Thompson Buffett Foundation), Praveen Ramakrishnan Geethakumari(Southwestern Medical Center), Mollie Reese(University of North Carolina at Chapel Hill), Maun R Baral(Washington University in St. Louis), Dilan A. Patel(Washington University in St. Louis), Matthew J. Matasar(Rutgers, The State University of New Jersey), Joseph Bennett(University of Kansas Medical Center), Andrew M. Evens(Rutgers, The State University of New Jersey), Joseph Lukowski(Nebraska Medical Center), Michele Stanchina(Sylvester Comprehensive Cancer Center), Cole Sterling(Sidney Kimmel Comprehensive Cancer Center), Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Joshua Friedman(Icahn School of Medicine at Mount Sinai), Graham T. Wehmeyer(Cornell University), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Matthew Gromowsky(Nebraska Medical Center), Narendranath Epperla(University of Utah), Timothy Voorhees(University of North Carolina at Chapel Hill), Chris Dittus(University of North Carolina at Chapel Hill), Youssef Youssef(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ross Terada(Brown University), Venkata Preetam Sandeep Kaduluri(Sidney Kimmel Comprehensive Cancer Center), Taylor Kujawa(Huntsman Cancer Institute), Benjamin Hane(University of Kansas Medical Center), Thomas Ollila(Brown University), Vidiya Srikakulapu(Southwestern Medical Center)
Cited by 0
Related Papers
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
|The Lancet Oncology|2022|429
Immune Checkpoint Inhibitors in Organ Transplant Patients
|Journal of Immunotherapy|2017|150
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy
|Annals of Oncology|2014|138
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
|Clinical Cancer Research|2020|115